12510 PROSPERITY DRIVE, SILVER SPRING, MD
Completes Sale of Women’s Health Segment to Cellution Biologics Inc.
Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
News
Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
Elutia Inc. Approves First Amendment to 2020 Incentive Award Plan
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
News, Material Contracts
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload